Aspen is changing hands at the top. Chair Kuseni Dlamini, a board member for 14 years, will step down at the drugmaker's December shareholder meeting, having told the board he won't stand for re-election. Veteran banker Ben Kruger takes over. Dlamini, a former head of Old Mutual's Africa, Asia and Latin America operations and a past Massmart chair, has helped steer Aspen through a debt-fuelled global expansion and the clean-up that followed.
A handover at a high point
The timing is deliberate. Aspen has just come through a strong year in which a run of high-value deals left it debt-free for the first time in decades, including the A$2.37 billion sale of its Asia-Pacific business, excluding China, to Australia's BGH Capital. That disposal was the deal that tipped Aspen into the black. For a company built on acquisitions, ending the year without debt marks a turning point. It is part of a broader board refresh Aspen describes as a leadership succession plan, complete with retirements, committee changes and governance-continuity measures. Incoming chair Kruger is a finance heavyweight: he joined Aspen's board in 2019, previously ran Standard Bank's corporate and investment banking arm, and sits on the boards of Stanbic Holdings and the JSE. His appointment signals continuity: he has known the board and the balance sheet for seven years. CEO Stephen Saad, who founded Aspen in 1997, told Business Day earlier this year the company was ready to ramp up growth now that it is debt-free.
The weight-loss windfall
The next chapter could be lucrative, and Aspen says Kruger will lead the charge. The company expects a windfall from cheap generic versions of GLP-1 weight-loss drugs as it moves to fill the gap left by rival Novo Nordisk, whose semaglutide patent lapses in many emerging markets this year. Reuters reckons the market for these drugs could be worth at least $100 billion by the end of the decade.
Aspen shares slipped 2.21% on the news, to R147.08, though they remain more than 25% higher for the year. The question now is whether Kruger can turn a clean balance sheet and a booming drug class into Aspen's next growth spurt.
